Tropical Splenomegaly Syndrome Follow-up
- Author: Mundeep K Kainth, DO, MPH; Chief Editor: Robert J Arceci, MD, PhD more...
Further Outpatient Care
Regular visits are essential to monitor the patient's clinical improvement and to document decreases in splenomegaly.
If chloroquine is used, monitor the patient for ophthalmologic effects with slit lamp, funduscopic, and visual field examinations.
At regular intervals, perform cardiovascular monitoring with ECG and echocardiography, along with other tests as indicated.
Further workup may be indicated to look for myopathy and peripheral neuritis.
Liver function tests may be performed regularly if the patient is receiving proguanil.
Resolution of splenomegaly is accompanied by an improvement of pancytopenia.
Further Inpatient Care
Because of the extended length of treatment often needed for hyperreactive malarial syndrome (HMS), monitoring for adverse effects is crucial.
Splenectomy is contraindicated, because of increased infection-associated mortality. However, if the patient's spleen was previously removed, guidelines for the care of asplenic patients should be followed (see Asplenia). Guidelines include the following:
- Antibiotic prophylaxis
- Aggressive management of suspected episodes of fever
- Appropriate immunizations
Inpatient & Outpatient Medications
Antimalarials are the mainstays of treatment for hyperreactive malarial syndrome (HMS) (see Medication). These drugs often need to be continued long-term (months to years). However, the exact length of treatment has not been ascertained.
Depending on the facilities available at the hospital, indications for transfer may be few. Medication can easily be started after the diagnosis is established. Supportive care, including blood transfusions and antibiotic therapy if indicated, is now commonplace in most hospitals.
For travelers to endemic areas, antimalarial prophylaxis is essential to minimize the risk of hyperreactive malarial syndrome (HMS).
Prophylaxis for residents of endemic areas is controversial and has not been shown to prevent HMS.
A study in Africa determined that the RTS,S/AS02D malaria vaccine was safe, well tolerated, and immunogenic in young infants. A recent report of a phase 3 trial of RTS,S/AS01 malaria vaccine showed modest protection (50% reduction) against clinical and severe malaria in African infants.
Long-term follow-up and studies are needed on whether a reduction in incidence of acute infection will lead to a decrease in the incidence of HMS.
Complications of hyperreactive malarial syndrome (HMS) include infections that may be serious and that may result in death. Trapping of hematopoietic elements in the enlarged spleen may cause thrombocytopenia, anemia, and neutropenia, with resultant problems.
A predisposition to develop malignancy remains unproven.
Hyperreactive malarial syndrome (HMS) is a chronic disease with mortality rates from 20-57% based on the degree of splenomegaly. Higher mortality rates are associated with treatment noncompliance. Bleeding and infection are the most common complications.
Splenectomy should be avoided because it increases the risk of fulminant infections.
The exact risk of development of malignancy has not been established.
The importance of antimalarial prophylaxis during visits to endemic areas should be emphasized to travelers.
Symptoms should be promptly attended to and evaluated, even if they occur in travelers who received prophylaxis. Hyperreactive malarial syndrome (HMS) may present months to years after leaving an endemic area.
Pitney WR. The tropical splenomegaly syndrome. Trans R Soc Trop Med Hyg. 1968. 62(5):717-28. [Medline].
Bryceson A, Fakunle YM, Fleming AF, et al. Malaria and splenomegaly. Trans R Soc Trop Med Hyg. 1983. 77(6):879. [Medline].
Fakunle YM. Tropical splenomegaly. Part 1: Tropical Africa. Clin Haematol. 1981 Oct. 10(3):963-75. [Medline].
Facer CA, Crane GG. Hyperreactive malarious splenomegaly. Lancet. 1991 Jul 13. 338(8759):115-6. [Medline].
Bates I, Bedu-Addo G. Review of diagnostic criteria of hyper-reactive malarial splenomegaly. Lancet. 1997 Apr 19. 349(9059):1178. [Medline].
Crane GG. Hyperreactive malarious splenomegaly (tropical splenomegaly syndrome). Parasitol Today. 1986 Jan. 2(1):4-9. [Medline].
Hoffman SL, Piessens WF, Ratiwayanto S, et al. Reduction of suppressor T lymphocytes in the tropical splenomegaly syndrome. N Engl J Med. 1984 Feb 9. 310(6):337-41. [Medline].
Piessens WF, Hoffman SL, Wadee AA, et al. Antibody-mediated killing of suppressor T lymphocytes as a possible cause of macroglobulinemia in the tropical splenomegaly syndrome. J Clin Invest. 1985 Jun. 75(6):1821-7. [Medline]. [Full Text].
Alkadarou T, Musa A, Alkadarou A, Mahfouz MS, Troye-Blomberg M, Elhassan AM. Immunological characteristics of hyperreactive malarial splenomegaly syndrome in sudanese patients. J Trop Med. 2013. 2013:961051. [Medline].
David-West AS. Relapses after withdrawal of proguanil treatment in tropical splenomegaly syndrome. Br Med J. 1974 Aug 24. 3(5929):499-501. [Medline].
Singh RK. Hyperreactive malarial splenomegaly in expatriates. Travel Med Infect Dis. 2007 Jan. 5(1):24-9. [Medline].
Pryor DS. Tropical splenomegaly in New Guinea. Q J Med. 1967 Jul. 36(143):321-36. [Medline].
Lowenthal MN, Hutt MS, Jones IG, Mohelsky V, O'Riordan EC. Massive splenomegaly in Northern Zambia. I. Analysis of 344 cases. Trans R Soc Trop Med Hyg. 1980. 74(1):91-8. [Medline].
Wu YH, Chuang SY, Hong WC, Lai YJ, Chang YL, Pang JH. In vivo and in vitro inhibitory effects of a traditional Chinese formulation on LPS-stimulated leukocyte-endothelial cell adhesion and VCAM-1 gene expression. J Ethnopharmacol. 2012 Mar 6. 140(1):55-63. [Medline].
Crane GG, Wells JV, Hudson P. Tropical splenomegaly syndrome in New Guinea. I. Natural history. Trans R Soc Trop Med Hyg. 1972. 66(5):724-32. [Medline].
Fakunle YM, Greenwood BM. Mortality in tropical splenomegaly syndrome. Trans R Soc Trop Med Hyg. 1980. 74(3):419. [Medline].
Bates I, Bedu-Addo G, Bevan DH, Rutherford TR. Use of immunoglobulin gene rearrangements to show clonal lymphoproliferation in hyper-reactive malarial splenomegaly. Lancet. 1991 Mar 2. 337(8740):505-7. [Medline].
De Iaco G, Saleri N, Perandin F, et al. Hyper-reactive malarial splenomegaly in a patient with human immunodeficiency virus. Am J Trop Med Hyg. 2008 Feb. 78(2):239-40. [Medline].
Foca E, Zulli R, Buelli F, De Vecchi M, Regazzoli A, Castelli F. P. falciparum malaria recrudescence in a cancer patient. Infez Med. 2009 Mar. 17(1):33-4. [Medline].
Martin-Peprah R, Bates I, Bedu-Addo G, Kwiatkowski DP. Investigation of familial segregation of hyperreactive malarial splenomegaly in Kumasi, Ghana. Trans R Soc Trop Med Hyg. 2006 Jan. 100(1):68-73. [Medline].
Bhatia KK, Crane GG. HLA heterozygosity and hyperreactive malarious splenomegaly in the Upper Watut Valley of Papua New Guinea. P N G Med J. 1989 Dec. 32(4):277-86. [Medline].
Van den Ende J, van Gompel A, van den Enden E, Taelman H, Vanham G, Vervoort T. Hyperreactive malaria in expatriates returning from sub-Saharan Africa. Trop Med Int Health. 2000 Sep. 5(9):607-11. [Medline].
Allam MM, Alkadarou TA, Ahmed BG, et al. Hyper-reactive Malarial Splenomegaly (HMS) in malaria endemic area in Eastern Sudan. Acta Trop. 2008 Feb. 105(2):196-9. [Medline].
Verma S, Aggarwal A. Hyper-reactive malarial splenomegaly: rare cause of pyrexia of unknown origin. Indian J Pediatr. 2007 Apr. 74(4):409-11. [Medline].
Bradaschia-Correa V, Barrence FA, Ferreira LB, Massa LF, Arana-Chavez VE. Effect of alendronate on endochondral ossification in mandibular condyles of growing rats. Eur J Histochem. 2012 May 25. 56(2):e24. [Medline]. [Full Text].
Mothe B, Lopez-Contreras J, Torres OH, Munoz C, Domingo P, Gurgui M. A case of hyper-reactive malarial splenomegaly. The role of rapid antigen-detecting and PCR-based tests. Infection. 2008 Mar. 36(2):167-9. [Medline].
Centers for Disease Control and Prevention. Malaria Diagnosis & Treatment in the United States. Available at http://www.cdc.gov/malaria/diagnosis_treatment/index.html. Accessed: March 12, 2013.
Leoni S, Buonfrate D, Angheben A, Gobbi F, Bisoffi Z. The hyper-reactive malarial splenomegaly: a systematic review of the literature. Malar J. 2015 Apr 29. 14:185. [Medline].
Manenti F, Porta E, Esposito R, Antinori S. Treatment of hyperreactive malarial splenomegaly syndrome. Lancet. 1994 Jun 4. 343(8910):1441-2. [Medline].
Aponte JJ, Aide P, Renom M, et al. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet. 2007 Nov 3. 370(9598):1543-51. [Medline].
Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med. 2012 Dec 13. 367(24):2284-95. [Medline].